# Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy

> **NCT04576689** · PHASE2 · COMPLETED · sponsor: **Ripple Therapeutics Pty Ltd** · enrollment: 60 (actual)

## Conditions studied

- Diabetic Macular Oedema
- Retinal Vein Occlusion with Macular Oedema

## Interventions

- **DRUG:** IBE-814 70ug
- **DRUG:** IBE-814 140ug

## Key facts

- **NCT ID:** NCT04576689
- **Lead sponsor:** Ripple Therapeutics Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-30
- **Primary completion:** 2023-04-25
- **Final completion:** 2024-03-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04576689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04576689, "Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04576689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*